Serum Albumin, E.g., Bsa, Hsa, Etc. Patents (Class 530/363)
Separation, purification or synthesis (Class 530/364)
  • Expression of Human Serum Albumin in Plastids
    Publication number: 20100304476
    Abstract: Human Serum Albumin (HSA) or an HSA fusion protein is expressed in plant plastids. A plastid transformation vector is made which contains an expression cassette that contains regulatory sequences, the coding region for HSA or an HSA fusion protein and a selectable marker coding sequence. The vector is used to transform a plant where the plant expresses the HSA or HSA fusion protein. HSA is isolated and purified from the plant. A preferred plant is tobacco.
    Type: Application
    Filed: May 18, 2010
    Publication date: December 2, 2010
    Inventor: Henry Daniell
  • MANUFACTURE AND USE OF MODIFIED POLYSACCHARIDE CHITOSAN BONDS AND A PROCESS TO IMPROVE THE PREPARATION OF HES-MEDICINAL SUBSTANCE COMPOUNDS
    Publication number: 20100298529
    Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.
    Type: Application
    Filed: April 26, 2007
    Publication date: November 25, 2010
    Inventors: Bernd Horst Meier, Nele Meier
  • TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT
    Publication number: 20100292148
    Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.
    Type: Application
    Filed: August 10, 2007
    Publication date: November 18, 2010
    Applicant: STARPHARMA PTY LTD.
    Inventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
  • IMMUNOTHERAPY TARGETING OF THE SHARED ABNORMAL CONFORMATIONAL STATE OF AMYLOIDOGENIC PEPTIDES/PROTEINS
    Publication number: 20100284909
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 11, 2010
    Applicant: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Serum albumin compositions for use in cleansing or dermatological products for skin or hair
    Patent number: 7829072
    Abstract: A hypoallergenic cleansing, cosmetic, conditioning or dermatological composition for treating skin or hair is provided which contains serum albumin in an amount effective to achieve cleansing, conditioning, wound debrisment, or other beneficial cosmetic or dermatological purpose for skin or hair, along with a suitable cleansing, conditioning, cosmetic, antibacterial or dermatological agent, vehicle, carrier or excipient. The compositions may be in any suitable form for treating skin or hair, such as a soap, shampoo, cream, oil, lotion, gel, gel-based ointment, and the like. The serum albumin compositions are preferably prepared using human serum albumin produced by recombinant means, and such compositions are useful in that they allow the albumin to be absorbed in the surface of skin or hair so as to replenish the structure of these tissues when utilized as a cleansing, cosmetic or dermatological agent.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 9, 2010
    Inventor: Daniel C. Carter
  • INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME
    Publication number: 20100279432
    Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.
    Type: Application
    Filed: July 8, 2010
    Publication date: November 4, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
  • COMPLEXATION OF FATTY ACID-CONJUGATED MOLECULES WITH ALBUMIN
    Publication number: 20100272644
    Abstract: The technology described herein is directed to conjugating various therapeutic or functional molecules, such small chemical drugs, peptides, oligonucleotides, isotopes and imaging regents with fatty acids, such as LCFAs. The fatty acid-conjugated molecules are complexed with a human serum albumin protein in vitro.
    Type: Application
    Filed: November 20, 2008
    Publication date: October 28, 2010
    Applicant: The University of the Sciences in Philadelphia
    Inventors: Zhlyu Li, Russell Digate
  • Triacetone Triperoxide and Diacetone Diperoxide Derivatives, Method for the Preparation and Use Thereof
    Publication number: 20100273193
    Abstract: This disclosure is drawn to a triacetone triperoxide derivative in accordance with the general formula (I) and a diacetone diperoxide derivative in accordance with the general formula (II) wherein R1 is a hydrogen residue or an optionally halogenated or perhalogenated C1 to C5 alkyl group, R2 represents a linker molecule, and X represents a reactive or activatable group. A method for the preparation of the TATP or DADP derivatives and the use thereof as antigen for the preparation of TATP- or DADP-specific antibodies or other binders is also disclosed. The antibodies are preferably used in a biosensor for the detection of TATP or DADP in air.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 28, 2010
    Applicant: BAM Bundesanstalt fur Materialforschung und-pruefung
    Inventors: Astrid Walter, Rudolf J. Schneider, Michael G. Weller
  • DIFFERENTIAL LABELLING METHOD
    Publication number: 20100267056
    Abstract: The invention relates to a method for differentially labelling one or more entities, together comprising distinct reactive sites. The invention further relates to an entity that has been labelled by a method according to the invention and to a diagnostic kit comprising a labelled entity and to a diagnostic kit to employ a method according to the invention.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 21, 2010
    Applicant: KREATECH BIOTECHNOLOGY B.V.
    Inventors: Eduard Gerhard Talman, Robertus Petrus Maria van Gijlswijk, Robert Jochem Heetebrij, Jacky Theo Maria Veuskens
  • Polypeptide compounds for inhibiting angiogenesis and tumor growth
    Publication number: 20100261653
    Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
    Type: Application
    Filed: September 14, 2009
    Publication date: October 14, 2010
    Applicant: VasGene Therapeutics, Inc.
    Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
  • Gastrin compositions and formulations, and methods of use and preparation
    Patent number: 7803766
    Abstract: The present invention concerns six novel variants of alternative splicing of the CD40 receptor The invention provides a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin/CCK receptor, to various carrier moieties, including the use of amino acid spacer regions, and use of bifunctional cross-linking reagents. Methods of treating a diabetes patient with the compositions are provided.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: September 28, 2010
    Assignee: Warath Pharmaceuticals, Inc
    Inventor: Antonio Cruz
  • Method for producing albumin conjugates containing gyrase inhibitors
    Patent number: 7803791
    Abstract: The present invention is directed to a Gyrase inhibitor-protein conjugate; in particular a Gyrase inhibitor-albumin conjugate. The present invention further provides methods of the treatment of inflammatory conditions and tumors. Methods of making and producing a Gyrase inhibitor-protein conjugate are also disclosed.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: September 28, 2010
    Assignee: Albupharm Heidelberg GmbH & Co. KG
    Inventors: Hannsjörg Sinn, Marcel Mülbaier
  • Composite organic-inorganic nanoclusters
    Publication number: 20100240870
    Abstract: Composite organic-inorganic nanoclusters (COINs) are provided that produce surface-enhanced Raman signals (SERS) when excited by a laser. The nanoclusters include metal particles and a Raman-active organic compound. The metal required for achieving a suitable SERS signal is inherent in the nanocluster and a wide variety of Raman-active organic compounds and combinations thereof can be incorporated into the nanocluster. In addition, polymeric microspheres containing the nanoclusters and methods of making them are also provided. The nanoclusters and microspheres can be used, for example, in assays for multiplex detection of biological molecules.
    Type: Application
    Filed: February 10, 2010
    Publication date: September 23, 2010
    Inventors: Xing Su, Jingwu Zhang, Lei Sun, Andrew A. Berlin
  • rBSA from K. lactis Expression, Secretion and Purification of Recombinant Bovine Serum Albumin (rBSA) from K. lactis and uses thereof
    Publication number: 20100240099
    Abstract: A recombinant BSA (rBSA) that (a) substantially lacks deoxyribonuclease activity as determined by incubating rBSA with linear DNA overnight and gel electrophoresis, (b) lacks animal viruses associated with animal-derived cell growth supplements; and (c) is capable of stabilizing DNA proteins is provided. Methods for making the rBSA and using it to stabilize enzymes are also provided.
    Type: Application
    Filed: March 30, 2007
    Publication date: September 23, 2010
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Paul A. Colussi, Thomas C. Evans, JR., Christopher H. Taron
  • Albumin fusion proteins
    Patent number: 7799759
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: September 21, 2010
    Assignees: Human Genome Sciences, Inc., Delta Biotechnology Limited
    Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
  • Tubular nanostructure targeted to cell membrane
    Publication number: 20100233781
    Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure targeted to a lipid bilayer membrane. The targeted tubular nanostructure can have a surface region configured to pass through a lipid bilayer membrane of a cell, a hydrophobic surface region flanked by two hydrophilic surface regions configured to form a pore in a lipid bilayer membrane of a cellular organelle, and at least one ligand configured to bind one or more cognates on the lipid bilayer membrane of the cellular organelle. The target cell can be, for example, a tumor cell, an infected cell, or a diseased cell in a subject. The tubular nanostructure can form a pore in the lipid bilayer membrane of the cellular organelle, e.g., mitochondria, which can permit transit or translocation of at least one compound across the membrane and cause cell death of the target cell.
    Type: Application
    Filed: January 30, 2009
    Publication date: September 16, 2010
    Inventors: Mahalaxmi Gita Bangera, Ed Harlow, Roderick A. Hyde, Muriel Y. Ishikawa, Edward K.Y. Jung, Eric C. Leuthardt, Nathan P. Myhrvold, Dennis J. Rivet, Elizabeth A. Sweeney, Clarence T. Tegreene, Lowell L. Wood, JR., Victoria Y.H. Wood
  • Biomaterial based on a hydrophilic polymeric carrier
    Publication number: 20100184223
    Abstract: The present invention relates to a biomaterial for cell or tissue culture, based on a polymeric carrier, which contains at least one crosslinkable hydrophilic polymer. The polymer is functionalized with groups that are selected from maleimide, vinylsulfonic, acrylate, alkyl halide, azirine, pyridyl, thionitrobenzene acid groups, or arylating groups. The invention relates further to a method of production of said biomaterial, and the use of particular functionalizing groups for the production of a biomaterial for the cultivation of tissue and/or cells. The biomaterial can have biofactors that exert a particular action on cells.
    Type: Application
    Filed: January 11, 2010
    Publication date: July 22, 2010
    Inventor: Helmut Wurst
  • HUMAN BLOOD PROTEINS EXPRESSED IN MONOCOT SEEDS
    Publication number: 20100183589
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 22, 2010
    Applicant: VENTRIA BIOSCIENCE
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Exposed proliferation-related peptides, ligands and methods employing the same
    Publication number: 20100173329
    Abstract: Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.
    Type: Application
    Filed: May 23, 2008
    Publication date: July 8, 2010
    Inventor: Staffan Eriksson
  • LEVETIRACETAM IMMUNOASSAYS
    Publication number: 20100173427
    Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.
    Type: Application
    Filed: October 22, 2009
    Publication date: July 8, 2010
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
  • Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation
    Publication number: 20100166700
    Abstract: The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.
    Type: Application
    Filed: February 28, 2007
    Publication date: July 1, 2010
    Applicant: OLIGASIS CORPORATION
    Inventor: Stephen A. Charles
  • Screening of Abundantly Secreted Proteins and Their Use as Fusion Partners for the Production of Recombinant Proteins
    Publication number: 20100159465
    Abstract: The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.
    Type: Application
    Filed: December 4, 2009
    Publication date: June 24, 2010
    Inventors: JUNG-HOON SOHN, JUNG-HOON BAE, HYUN-JIN KIM, KWANG-MOOK LIM, SEUNG LI KIM
  • huTNFR1 Selective Antagonists
    Publication number: 20100150916
    Abstract: The present invention relates to a ligand which specifically binds to the human tumor necrosis factor type 1 receptor (huTNFR1), the ligand comprising one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in human beings and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention further relates to a nucleic acid encoding said ligand and to a pharmaceutical composition for the treatment of disorders connected to huTNFR1.
    Type: Application
    Filed: March 13, 2008
    Publication date: June 17, 2010
    Applicant: UNIVERSITÄT STUTTGART
    Inventors: Klaus Pfizenmaier, Peter Scheurich, Roland Kontermann, Sabine Münkel
  • Microparticles with enhanced covalent binding capacity and their uses
    Patent number: 7732575
    Abstract: Disclosed are proteins which are covalently bound to a solid support at a first temperature where they have a first configuration, and then biomolecules are attached to the bound proteins at a higher temperature at which the proteins have more exposed functional groups, each such group being capable of covalently bonding to a biomolecule. The biomolecule can be, for example, a nucleic acid, including an amine functionalized oligonucleotide. The proteins can include, BSA (Bovine Serum Albumin) which can be bound using a reaction with the surface of a tosyl-activated microparticle.
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: June 8, 2010
    Assignee: Bioarray Solutions, Ltd.
    Inventors: Xinwen Wang, Sukanta Banerjee
  • HUMAN M2e PEPTIDE IMMUNOGENS
    Publication number: 20100135955
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: November 12, 2009
    Publication date: June 3, 2010
    Applicant: Theraclone Sciences, Inc.
    Inventors: Matthew Moyle, Jennifer Mitcham
  • Peptide antagonists of TGF-beta family members and therapeutic uses thereof
    Patent number: 7723473
    Abstract: This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of re-epithelialization during wound healing.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 25, 2010
    Assignee: St. Louis University
    Inventor: Jung San Huang
  • TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR
    Publication number: 20100121033
    Abstract: The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: November 21, 2007
    Publication date: May 13, 2010
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, David Fabrizio, Martin C. Wright, Patrick Gage, John Mendlein
  • ACID SOLUBLE PROTEINS FROM MICELLAR CASEIN
    Publication number: 20100111933
    Abstract: The present invention relates to a milk fraction obtainable by acidification of micellar casein and separation from precipitated casein named acid soluble protein from micellar casein. It was found that the milk fraction and especially certain sub-fractions thereof are bioactive and promote GLP-1 release in vitro. Based on these results, acid soluble protein from micellar casein may be useful in the treatment and the prevention of diabetes type II, obesity and may further be added to formulas directed at other purposes addressing the gastro-intestinal tract.
    Type: Application
    Filed: October 23, 2009
    Publication date: May 6, 2010
    Inventors: Sandrine GREMLICH, Lionel Bovetto, Catherine Mace
  • MULTIMERIC Fc RECEPTOR POLYPEPTIDES INCLUDING A MODIFIED Fc DOMAIN
    Publication number: 20100112080
    Abstract: A soluble multimeric polypeptide or protein is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more Fc binding regions linked in a head to tail arrangement, at least one of which is derived from an Fc?R type receptor, and an Fc domain of an immunoglobulin which has been modified to reduce or prevent binding to the said Fc binding regions and/or to alter effector function. Also described are polynucleotide molecules encoding the polypeptide or protein and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.
    Type: Application
    Filed: December 13, 2007
    Publication date: May 6, 2010
    Inventors: Mark Phillip Hogarth, Bruce David Wines
  • SYSTEMS, METHODS, AND COMPOSITIONS FOR PREVENTION OF TISSUE ADHESION
    Publication number: 20100099852
    Abstract: A blended electrophilic material with a first component having a functionality of at least three and a second component having a functionality of two is mixed with a nucleophilic material. The blended electrophilic material cross-links with the nucleophilic material to form a non-liquid, three dimensional structure which can applied, e.g., as an adhesion barrier.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 22, 2010
    Applicant: NEOMEND, INC.
    Inventors: Charles Vaughn Cassingham, William Jerome Mezger
  • Exendin agonist analogs to treat diabetes
    Patent number: 7700549
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: April 20, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young
  • Blood replacement product
    Patent number: 7696176
    Abstract: A composition comprising Human Serum Albumin and an Amino Acid Solution, a method of making the same, and a method for use, including treating acute hypovolemia due to any number of medical conditions due to sepsis with shock, hemorrhagic shock, hypovolemic shock, burn injury, capillary leak syndrome, hypoalbuminemia, nephritic syndrome, or multi-organ failure with third space fluid loss from any other medical disease.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: April 13, 2010
    Inventor: William J. Norberg
  • Exendin agonist compounds
    Patent number: 7696161
    Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: April 13, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett
  • Aqueous microfabrication of functional bioelectronic architectures
    Publication number: 20100075393
    Abstract: The present invention is an apparatus, system and method for forming nanoscale architectures having nanoparticles bound thereto. The present invention provides a photon beam crosslinked polymer matrix, wherein the crosslinked matrix includes one or more polymers crosslinked to one or more crosslinking agents and one or more protein-coated metal nanoparticles.
    Type: Application
    Filed: May 23, 2006
    Publication date: March 25, 2010
    Applicant: Board of Regents,The University of Texas System
    Inventors: Jason B. Shear, Keith J. Stevenson, Ryan T. Hill, Jennifer L. Lyon
  • Methods of treating diabetes with albumin-conjugated exendin peptides
    Patent number: 7683030
    Abstract: Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: March 23, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. Prickett, Andrew A. Young
  • LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR
    Publication number: 20100056439
    Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
    Type: Application
    Filed: December 5, 2006
    Publication date: March 4, 2010
    Applicant: DOMANTIS LIMITED
    Inventors: Roland Beckmann, Rudolf M T De Wildt, Steve Holmes, Olga Ignatovich, Laurent S Jespers, Haiqun Liu, Malgorzata Pupecka, Armin Sepp, Michael Steward
  • Identities, specificities, and use of twenty two (22) differentially expressed protein biomarkers for blood based diagnosis of breast cancer
    Publication number: 20100004871
    Abstract: The present invention discloses twenty two 22 protein biomarkers of breast cancer. More specifically, the present invention discloses the identities, specificities, and uses of up to twenty two (22) protein biomarkers in blood serum for distinguishing between patients with earlier and later stages of breast cancer, patients with benign breast diseases or abnormalities, and normal individuals lacking breast abnormalities.
    Type: Application
    Filed: November 17, 2008
    Publication date: January 7, 2010
    Applicant: Power3 Medical Products, Inc.
    Inventor: Ira L. Goldknopf
  • LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS
    Publication number: 20090312259
    Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
    Type: Application
    Filed: July 19, 2009
    Publication date: December 17, 2009
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
  • Human cDNA Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their Use
    Publication number: 20090286954
    Abstract: The invention provides novel human full-length cDNA clones, novel polynucleotides, related polypeptides, related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these cDNA clones, polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic and therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders.
    Type: Application
    Filed: April 15, 2009
    Publication date: November 19, 2009
    Inventors: Lewis T. Williams, Keting Chu, Ernestine Lee, Kevin Hestir, Justin Wong, Stephen K. Doberstein
  • Recombinant Production of Serum Albumin
    Publication number: 20090280534
    Abstract: The present invention relates to modified nucleotide sequences encoding serum albumin, wherein the mRNA sequence has been codon optimized for expression in a filamentous host cell. Furthermore the present invention relates to serum albumin produced in filamentous fungi or loaded by contacting serum albumin with an extract of a filamentous fungi culture. In an-other aspect the present invention relates to the use of said serum albumin in serum free cell culture media and also to a method of drying and agglomerating serum albumin thereby im-proving wettability and dispersability.
    Type: Application
    Filed: December 22, 2005
    Publication date: November 12, 2009
    Applicant: Novozymes A/S
    Inventors: Bjarke Christensen, Carsten Hjort, Thomas Agersten Poulsen, Poul Bach
  • Agent for improving circulatory disorder
    Publication number: 20090275732
    Abstract: Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in which a porphyrin metal complex is clathrated in albumin, it was found that the compound efficiently improves decreases in blood flow in circulatory disorders and fully prevents or improves tissue damage, thus the invention was achieved. That is, the invention is directed to an agent for improving a circulatory disorder including a compound in which a porphyrin metal complex is clathrated in albumin.
    Type: Application
    Filed: April 27, 2006
    Publication date: November 5, 2009
    Inventors: Ichiro Hirotsu, Yuki Ohkawa, Masanori Nozako, Saori Suzuki, Yukiko Kuwata, Makoto Sato
  • Exendins and exendin agonists modified with albumin
    Patent number: 7608692
    Abstract: Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: October 27, 2009
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. Prickett, Andrew A. Young
  • Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
    Patent number: 7605130
    Abstract: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: October 20, 2009
    Assignee: Medical College of Ohio
    Inventors: Ragheb Assaly, John D. Dignam, Joseph I. Shapiro
  • HUMAN BLOOD PROTEINS EXPRESSED IN MONOCOT SEEDS
    Publication number: 20090258004
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Application
    Filed: November 27, 2007
    Publication date: October 15, 2009
    Inventors: Ning Huang, Raymond L. Rodriquez, Frank E. Hagie, David M. Stalker
  • Process of high purity albumin production
    Patent number: 7601515
    Abstract: A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 13, 2009
    Assignee: Novozymes Biopharma UK Limited
    Inventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
  • Albumin fusion proteins
    Patent number: 7592010
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 22, 2009
    Assignees: Human Genome Sciences, Inc., Delta Biotechnology Limited
    Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
  • Mycophenolic acid immunogens and antibodies
    Publication number: 20090215993
    Abstract: Described are immunogenic compounds useful for generation of antibodies which are highly specific for mycophenolic acid which do not react or have substantially no cross-reactivity with the glucuronide metabolites of mycophenolic acid, especially the acyl-glucuronide metabolite.
    Type: Application
    Filed: October 24, 2008
    Publication date: August 27, 2009
    Inventors: Mitali Ghoshal, Raymond Hui, Shaker Rashid
  • METHOD FOR THE PREPARATION OF SPECIFIC ANTIBODIES AGAINST SACCHARIDIC ANTIGENS
    Publication number: 20090202580
    Abstract: The present invention relates to new compounds useful for the stimulation of the production of antibodies. Said compounds comprises a saccharidic tumor antigen and a polymeric scaffold. The present invention also encompasses conjugated compounds useful in ELISA assay for the selection of antibodies against saccharidic antigens.
    Type: Application
    Filed: June 19, 2007
    Publication date: August 13, 2009
    Applicant: Bracco Imaging SpA
    Inventors: Fulvio Uggeri, Cristiana Campa, Sergio Paoletti, Anna Coslovi, Alfonso Colombatti, Carla Danussi
  • ACTIVATED LABELING REAGENTS AND METHODS FOR PREPARING AND USING THE SAME
    Publication number: 20090203879
    Abstract: The present invention relates in general to labeling reagents useful for labeling biomolecules. In particular, the invention provides activated labeling reagents, methods of preparing the same, methods of using the labeled reagents for synthesizing a labeled biomolecule, kits that include reagents for a labeling a biomolecule and kits containing for labeled biomolecules.
    Type: Application
    Filed: November 22, 2005
    Publication date: August 13, 2009
    Inventor: Stela Gengrinovitch
  • HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBOSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVENTIONS
    Publication number: 20090202607
    Abstract: Heparin-like compounds inhibit collagen-induced platelet aggregation in flowing whole blood. The compounds share properties displayed by native mast-cell derived heparin proteoglycans (HEP-PG) and/or heparin glycosaminoglycan (HEP-GAG) molecules. The compounds are useful in prevention and treatment of severe vascular disorders including arterial thrombosis.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 13, 2009
    Applicant: JENNY JA ANTTI WIHURIN RAHASTO
    Inventors: Riitta Lassila, Petri Kovanen, Ken Lindstedt